ArticleThe Lancet regional health. Europe2025
Humoral and cellular responses to a fifth bivalent SARS-CoV-2 vaccine dose in patients with immune-mediated inflammatory diseases on tumour necrosis factor inhibitors: a prospective cohort study.
Hilde S Ørbo et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.